Applied for trials of Covavax, hope to launch it by June: SII

Novavax Inc had declared on Friday (January 29) that, as per a trial conducted in the UK, its vaccine has an efficacy of 83.9 per cent

Adar Poonawalla
Serum Institute of India's CEO Adar Poonawalla had promised to manufacture around 400 million doses of the vaccine for low and middle-income countries by the end of 2020, but couldn't keep it due to several roadblocks | File Photo

Serum Institute of India (SII) has applied for starting trials of another COVID-19 vaccine, Covavax, in association with Novavax, in India. CEO of SII Adar Poonawalla made this announcement on Saturday (January 30). He said he hopes to launch the vaccine by June 2021.

Poonawalla tweeted: “Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch COVOVAX by June 2021.”

Novavax Inc had declared on Friday (January 29) that, as per a trial conducted in the UK, its vaccine has an efficacy of 83.9 per cent and, according to a preliminary analysis, it was nearly as effective in protecting against the new contagious variant first discovered in the UK.

AdvertisementChoco-pie Ad

Also read: Fire caused damages worth ₹1,000 cr, Covishield supply won’t be hit: Serum

According to Novavax, it began making updated versions of its vaccine in early January to protect against new strains and said it plans to start clinical testing of these new vaccines in the second quarter of 2021.

SII is manufacturing Covishield developed by AstraZeneca and Oxford, and has received emergency use authorisation from the government for the vaccine. The Centre has purchased 11 million doses of the vaccine for its vaccination programme.

The government started the nationwide vaccination drive on January 16, and aims to inoculate 3 crore healthcare and frontline workers in the first phase.

 

 

 

 

 

 

 

 

 

Get breaking news and latest updates from India
and around the world on thefederal.com
FOLLOW US: